hrp0095p1-238 | Diabetes and Insulin | ESPE2022

Faster-acting insulin Fiasp vs insulin Novorapid in type 1 diabetes children and adolescents with sensor-augmented pump therapy

Xatzipsalti Maria , Triantafillidou Antigoni , Kourousi Giannoula , Patouni Konstantina , Bourousis Evangelos , Kassari Elisavet , Delis Dimitrios , Vazeou Andriani

Introduction: Rapid-acting insulin analogues have been developed to mimic more closely the physiological action of endogenous insulin. However, they still have a delayed onset of action and a longer duration compares to endogenous insulin. Therefore, newer insulin analogues have been developed with a faster onset and a shorter duration of action.Aim: To evaluate the efficacy of rapid-acting insulin analogues (Novorapid) ...